Tags

Type your tag names separated by a space and hit enter

Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Diagn Microbiol Infect Dis. 2014 Apr; 78(4):422-8.DM

Abstract

Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a new cephalosporin with bactericidal activity against resistant Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant strains of Streptococcus pneumoniae, and commonly isolated Gram-negative organisms, including ceftriaxone-susceptible Enterobacteriaceae. We evaluated the in vitro activity of ceftaroline and selected comparator agents against bacterial isolates collected from patients with acute bacterial skin and skin structure infections (ABSSSIs) in the USA. A total of 6222 isolates were collected from 67 medical centers distributed across all nine USA census regions between 2009 and 2011 and tested for susceptibility by reference broth microdilution methods. Ceftaroline was very active against S. aureus (MIC50/90, 0.5/1 μg/mL; 99.6% susceptible), including MRSA (MIC50/90, 0.5/1 μg/mL; 99.1% susceptible). Against β-hemolytic streptococci, the activity of ceftaroline (MIC50/90, ≤0.015/0.03 μg/mL; 100.0% susceptible) was comparable to that of both penicillin (MIC50/90, ≤0.06/≤0.06 μg/mL; 100.0% susceptible) and ceftriaxone (MIC50/90, ≤0.25/≤0.25 μg/mL; 100.0% susceptible). Ceftaroline was also highly active against viridans group streptococci (MIC50/90, 0.03/0.06 μg/mL). Similar to ceftriaxone and ceftazidime, ceftaroline was active against wild-type strains of Escherichia coli (MIC50/90, 0.12/0.25 μg/mL; 94.0% susceptible) and Klebsiella pneumoniae (MIC50/90, 0.12/0.25 μg/mL; 96.8% susceptible); however, the ceftaroline activity was compromised among strains with an extended-spectrum β-lactamase-phenotype (MIC50/90, >32/>32 μg/mL for both E. coli and K. pneumoniae). In summary, ceftaroline showed potent activity against a large contemporary collection (6222) of bacterial isolates associated with ABSSSI in the USA.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA. Electronic address: helio-sader@jmilabs.com.JMI Laboratories, North Liberty, IA, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24445158

Citation

Pfaller, Michael A., et al. "Ceftaroline Activity Against Bacterial Organisms Isolated From Acute Bacterial Skin and Skin Structure Infections in United States Medical Centers (2009-2011)." Diagnostic Microbiology and Infectious Disease, vol. 78, no. 4, 2014, pp. 422-8.
Pfaller MA, Flamm RK, Sader HS, et al. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagn Microbiol Infect Dis. 2014;78(4):422-8.
Pfaller, M. A., Flamm, R. K., Sader, H. S., & Jones, R. N. (2014). Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagnostic Microbiology and Infectious Disease, 78(4), 422-8. https://doi.org/10.1016/j.diagmicrobio.2013.08.027
Pfaller MA, et al. Ceftaroline Activity Against Bacterial Organisms Isolated From Acute Bacterial Skin and Skin Structure Infections in United States Medical Centers (2009-2011). Diagn Microbiol Infect Dis. 2014;78(4):422-8. PubMed PMID: 24445158.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). AU - Pfaller,Michael A, AU - Flamm,Robert K, AU - Sader,Helio S, AU - Jones,Ronald N, Y1 - 2014/01/18/ PY - 2013/08/13/received PY - 2013/08/23/revised PY - 2013/08/27/accepted PY - 2014/1/22/entrez PY - 2014/1/22/pubmed PY - 2014/11/5/medline KW - Anti-MRSA cephalosporins KW - MRSA KW - Staphylococcus aureus SP - 422 EP - 8 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 78 IS - 4 N2 - Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a new cephalosporin with bactericidal activity against resistant Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant strains of Streptococcus pneumoniae, and commonly isolated Gram-negative organisms, including ceftriaxone-susceptible Enterobacteriaceae. We evaluated the in vitro activity of ceftaroline and selected comparator agents against bacterial isolates collected from patients with acute bacterial skin and skin structure infections (ABSSSIs) in the USA. A total of 6222 isolates were collected from 67 medical centers distributed across all nine USA census regions between 2009 and 2011 and tested for susceptibility by reference broth microdilution methods. Ceftaroline was very active against S. aureus (MIC50/90, 0.5/1 μg/mL; 99.6% susceptible), including MRSA (MIC50/90, 0.5/1 μg/mL; 99.1% susceptible). Against β-hemolytic streptococci, the activity of ceftaroline (MIC50/90, ≤0.015/0.03 μg/mL; 100.0% susceptible) was comparable to that of both penicillin (MIC50/90, ≤0.06/≤0.06 μg/mL; 100.0% susceptible) and ceftriaxone (MIC50/90, ≤0.25/≤0.25 μg/mL; 100.0% susceptible). Ceftaroline was also highly active against viridans group streptococci (MIC50/90, 0.03/0.06 μg/mL). Similar to ceftriaxone and ceftazidime, ceftaroline was active against wild-type strains of Escherichia coli (MIC50/90, 0.12/0.25 μg/mL; 94.0% susceptible) and Klebsiella pneumoniae (MIC50/90, 0.12/0.25 μg/mL; 96.8% susceptible); however, the ceftaroline activity was compromised among strains with an extended-spectrum β-lactamase-phenotype (MIC50/90, >32/>32 μg/mL for both E. coli and K. pneumoniae). In summary, ceftaroline showed potent activity against a large contemporary collection (6222) of bacterial isolates associated with ABSSSI in the USA. SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/24445158/Ceftaroline_activity_against_bacterial_organisms_isolated_from_acute_bacterial_skin_and_skin_structure_infections_in_United_States_medical_centers__2009_2011__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(13)00473-2 DB - PRIME DP - Unbound Medicine ER -